Pyrotinib

Generic Name: Pyrotinib

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₃₁ClN_₆O_₃

CAS Number: 1269662-73-8

Unique Ingredient Identifier: CJN36EQM0H

Background: Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).

Clinical Trials

The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study

Phase 2

Recruiting

Conditions: HER2 Positive Breast Cancer
Pyrotinib Treatment

Interventions: Drug: pyrotinib

First Posted Date: 2025-05-06

Last Posted Date: 2025-05-06

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 964

Registration Number: NCT06958627

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

Recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Pyrotinib

First Posted Date: 2024-12-31

Last Posted Date: 2025-01-01

Lead Sponsor: zhangjie

Target Recruit Count: 60

Registration Number: NCT06754059

Locations: 🇨🇳
Fujian Union Medical College Hospital, Fuzhou, Fujian, China

Pyrotinib in HER2-positive Early Breast Cancer

Not Applicable

Not yet recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Pyrotinib

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-11

Lead Sponsor: Nie Jianyun

Target Recruit Count: 156

Registration Number: NCT06718335

Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain Metastasis

Phase 1

Recruiting

Conditions: Breast Cancer Metastatic
Breast Cancer Brain Metastases

Interventions: Drug: SHR-A1811
Drug: Pyrotinib
Drug: Bevacizumab

First Posted Date: 2024-12-05

Last Posted Date: 2025-02-06

Lead Sponsor: Fudan University

Target Recruit Count: 74

Registration Number: NCT06718933

Locations: 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-18

Lead Sponsor: Peking University Shenzhen Hospital

Target Recruit Count: 200

Registration Number: NCT06692491

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Phase 2

Recruiting

Conditions: Mutation
Lung Cancer Stage III

Interventions: Drug: Glecirasib
Drug: Dabrafenib+Trametinib
Drug: Larotrectinib
Drug: Crizotinib
Drug: Sunvozertinib
Drug: Pralsetinib
Drug: Savolitinib
Drug: Pyrotinib
Drug: Ensartinib

First Posted Date: 2024-08-21

Last Posted Date: 2024-12-10

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 120

Registration Number: NCT06563999

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

Not Applicable

Not yet recruiting

Conditions: Breast Cancer
RWS
Pyrotinib

Interventions: Drug: Pyrotinib

First Posted Date: 2024-07-10

Last Posted Date: 2024-07-10

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 500

Registration Number: NCT06495541

Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine

First Posted Date: 2024-07-03

Last Posted Date: 2024-07-03

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 109

Registration Number: NCT06483386

Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs

Phase 2

Not yet recruiting

Conditions: Metastatic Breast Cancer in the Brain

Interventions: Drug: pyrotinib plus capecitabine

First Posted Date: 2024-06-26

Last Posted Date: 2024-06-26

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 32

Registration Number: NCT06475443

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Phase 3

Recruiting

Conditions: First-line Treatment
HER2-positive Metastatic Breast Cancer

Interventions: Drug: disitamab vedotin
Drug: trastuzumab
Drug: Pyrotinib
Drug: Pertuzumab
Drug: taxane drug

First Posted Date: 2024-02-26

Last Posted Date: 2024-02-26

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 312

Registration Number: NCT06278870

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy